Study identifies two promising molecular targets for drug development in recurrent and metastatic cervical cancer

NRG Oncology GOG-0240 is the phase 3 randomized trial that demonstrated that the incorporation of bevacizumab with chemotherapy resulted in a statistically significant and clinically meaningful survival benefit for women with recurrent and metastatic cervical carcinoma (NCT00803062). GOG-0240 was a proof of concept in anti-angiogenesis therapy and a proof of principle in supportive care and led directly to an indication for bevacizumab in this disease in more than 60 countries.

Leave A Comment

Your email address will not be published. Required fields are marked *